Date: Monday 13 May 2013
Bioquell: Investec shifts target price from 136p to 141p and keeps a hold recommendation.
| London close: Stocks end week on a high | 10-May-2013 | ShareCast |
| FTSE 100 movers: BT Group charges into the top s... | 10-May-2013 | ShareCast |
| London midday: All eyes on Bernanke and G7 | 10-May-2013 | ShareCast |
| London open: Now it´s Japan´s turn | 10-May-2013 | ShareCast |
| Shire wins trial over ulcerative colitis drug | 10-May-2013 | ShareCast |
| SHIRE PLC - Transaction in Own Shares | 16-May-2013 | 07:00 | PR Newswire |
| SHIRE PLC - Shire Wins Patent Trial Against Wats... | 09-May-2013 | 16:58 | PR Newswire |
| SHIRE PLC - Transaction in Own Shares | 09-May-2013 | 07:00 | PR Newswire |
| SHIRE PLC - Purchase of Shares by Employee Benef... | 08-May-2013 | 15:00 | PR Newswire |
| SHIRE PLC - Transaction in Own Shares | 08-May-2013 | 07:00 | PR Newswire |
| Investment Column:Shire | 05-Aug-2010 | The Independent |
| FTSE latest: Shell down; RBS, Lloyds up | 29-Oct-2009 | Daily Mail |
| FTSE 100 latest: Miners lead the way, builders b... | 22-Sep-2009 | Daily Mail |
| Investment Column:Shire | 06-Aug-2009 | The Independent |
| Tempus:Shire | 06-Aug-2009 | Times |
| Currency | UK Pounds |
| Share Price | 2,050.00p |
| Change Today | -4.00p |
| % Change | -0.19 % |
| 52 Week High | 2,153.00 |
| 52 Week Low | 1,727.00 |
| Volume | 1,392,744 |
| Shares Issued | 554.15m |
| Market Cap | £11,360m |
| Beta | 0.82 |
| RiskGrade | 128 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income |
|
|---|
| Growth |
|
|---|
| Strong Buy | 20 |
| Buy | 2 |
| Neutral | 6 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 28 |

| Latest | Previous | |
|---|---|---|
| 2nd Interim | Interim | |
| Ex-Div | 06-Mar-13 | 05-Sep-12 |
| Paid | 09-Apr-13 | 04-Oct-12 |
| Amount | 14.60¢ | 2.73¢ |
| Time | Volume / Share Price |
| 16:41 | 20,000 @ 2,049.63p |
| 16:41 | 11,623 @ 2,048.17p |
| 16:35 | 386,432 @ 2,050.00p |
| 16:29 | 66 @ 2,050.00p |
| 16:29 | 32 @ 2,050.00p |
| Chair | Matthew Emmens |
| CEO | Angus Russell |
| CFO | Graham Hetherington |
| CEO | Flemming Ornskov |
You are here: research